The short version of Research chemical fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-08. Anything still debated is marked as such rather than presented as settled.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
| Property | Value | Notes |
|---|---|---|
| Common route | Intranasal | Also injected in some animal work |
| Solubility class | Freely soluble in water | Solid form is hygroscopic |
| Typical storage | About -20 degrees Celsius | Keep desiccated and dark |
| Purity method | Reverse-phase HPLC | Reported as area percent |
| Confirmatory method | Mass spectrometry | Verifies expected molecular mass |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
== Causes == Point mutations usually take place during DNA replication. DNA replication occurs when one double-stranded DNA molecule creates two single strands of DNA, each of which is a template for the creation of the complementary strand. A single point mutation can change the whole DNA sequence. Changing one purine or pyrimidine may change the amino acid that the nucleotides code for. Point mutations may arise from spontaneous mutations that occur during DNA replication. The rate of mutation may be increased by mutagens. Mutagens can be physical, such as radiation from UV rays, X-rays or extreme heat, or chemical (molecules that misplace base pairs or disrupt the helical shape of DNA). Mutagens associated with cancers are often studied to learn about cancer and its prevention. There are multiple ways for point mutations to occur. First, ultraviolet (UV) light and higher-frequency light have ionizing capability, which in turn can affect DNA. Reactive oxygen molecules with free radicals, which are a byproduct of cellular metabolism, can also be very harmful to DNA. These reactants can lead to both single-stranded and double-stranded DNA breaks. Third, bonds in DNA eventually degrade, which creates another problem to keep the integrity of DNA to a high standard. There can also be replication errors that lead to substitution, insertion, or deletion mutations.
HITS-CLIP (High-throughput sequencing of RNA isolated by crosslinking immunoprecipitation or CLIP-seq) PAR-CLIP (Photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation) iCLIP (Individual nucleotide-resolution cross-linking and immunoprecipitation) eCLIP (Enhanced cross-linking and immunoprecipitation followed by high-throughput sequencing) sCLIP (Simple cross-linking and immunoprecipitation)
== Career == In December 1986, Cameron joined the Department of Chemical Engineering at the University of Wisconsin—Madison, as an assistant professor and advanced to full professor. The focus of his research was metabolic engineering (a field now more commonly known as synthetic biology) and industrial microbiology. One of his first projects was the engineering of the microbial pathway for 1,3-propanediol in Escherichia coli. This work was an early step in a process that was eventually commercialized by DuPont and Tate & Lyle. He is also the inventor of a process for the microbial production of 3-hydroxypropionic acid, which provides a bio-based route to industrial chemicals such as acrylic acid. In 1996 he did a sabbatical at the ETH Zurich (Switzerland) in the laboratory of James (Jay) E. Bailey. In 1998 he took a leave of absence to start the Biotechnology Development Center (BioTDC) at Cargill, Inc. in Minneapolis. In 2000 he officially left the University of Wisconsin. Cameron was at Cargill, Inc. from 1998 to 2006, where he was Director of Biotechnology and chief scientist. While at Cargill he worked closely with NatureWorks on the development of a low-pH process for lactic acid as a feedstock for polylactic acid. He and his team also worked with Cargill Ventures on deal-sourcing and due-diligence. In June 2006, Cameron moved from Cargill to join the newly formed Silicon Valley venture capital firm, Khosla Ventures, as chief scientific officer. In 2008, Cameron returned to the Midwest to help Piper Jaffray build and grow its clean tech investment business.
Sources: en.wikipedia.org
However, this difference is usually neglected most of the time (that is whenever we are not dealing with processes such as sound absorption and attenuation of shock waves, where second viscosity coefficient becomes important) by explicitly assuming
=== Insulin-like growth factors === Insulin-like growth factors (IGF) assist bone growth in the body. IGF's are single-chain polypeptides that are similarly structured to insulin. There are 2 IGFs: Insulin-like growth factor 1 (IGF-1), and Insulin-like growth factor 2 (IGF-2). IGF-1 is induced by growth hormone (GH), and targets cartilage, stimulating cell bone cell proliferation. Studies carried out by Yakar S, Rosen CJ have shown in animal models that IGF-1 can enhance longitudinal growth, periosteal circumference, and bone mineral density. IGF-1 is responsible for increasing overall body size, longitudinal bone size, and height, especially during puberty.
Politicians are usually targeted for three reasons: (1) Political figures who are honest pose a direct threat to organized crime, and are consequently killed by cartels; (2) Politicians make arrangements to protect a certain cartel and are killed by a rival cartel; and (3) A cartel kills politicians to heat the turf of the rival cartel that operates in the area.
Sources: en.wikipedia.org
Most published work uses intranasal application, either as drops or as a nasal spray. Injection routes appear in a smaller set of animal experiments. Oral use is uncommon in the literature because peptide breakdown and poor absorption limit this route.
Reported human trials are few, brief and originate mainly from one country. They describe effects on anxiety-related measures, but sample sizes are small and reporting is limited. The results are widely regarded as preliminary rather than confirmed.
Reverse-phase liquid chromatography is used to assess purity and separation of related impurities. Mass spectrometry confirms that the observed molecular mass matches the expected peptide. A certificate of analysis from the supplier is the usual document of record.
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.